
OPN and ACCP Hematology/Oncology PRN Journal Club - October 2026
- The OPN and the ACCP H/O PRN Journal Club is a monthly virtual (online) event.
Overview
DESTINY-Breast05 study is a phase 3, open-label, randomized trial that evaluated post-neoadjuvant trastuzumab deruxtecan compared with trastuzumab emtansine in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual disease after neoadjuvant therapy who are at high risk for recurrence. This presentation will review the study methods, key outcomes and safety data, validity, as well as relevance for clinical practice.
Identified Gap(s)
Oncology pharmacists lack regular, structured opportunities to engage with emerging literature and apply new evidence to clinical practice. The rapid pace of drug development, evolving treatment guidelines, and increasing complexity of oncology care demand ongoing education that is interactive and peer driven. The absence of oncology-specific journal clubs limits pharmacists’ ability to stay current, critically evaluate research, and contribute fully to multidisciplinary care—ultimately impacting patient outcomes.
Description of Current State
Oncology pharmacists are increasingly stepping into high-value, patient-focused roles due to the growing complexity of cancer care and shortages of oncologists and nurses. With over 50 new cancer drugs approved in 2024 alone, the need for pharmacists to stay current with treatment advances is critical.1 However, educational gaps persist, as pharmacists often lack access to oncology-focused continuing education. As drug experts on the care team, they must be equipped to manage complex therapies and fill care gaps—particularly in areas like pregnancy-associated cancer and supportive care.
Description of desired/achievable state
Oncology pharmacists will have access to a virtual, accredited journal club designed to support continuous learning and clinical application of emerging evidence. This interactive platform will foster peer-to-peer discussion, enhance critical literature appraisal skills, and empower pharmacists to deliver evidence-based care in complex scenarios, ultimately strengthening their role within the oncology care team.
Upon completion of this journal club, you will:
- Discuss potential sources of bias, limitations, and strengths of each clinical study
- Assess the validity, relevance, and applicability of the latest clinical research studies
Target Audience
This activity is intended for oncology pharmacists, pharmacy techs, and pharmacy residents who are involved in the treatment of cancer patients.
Presented By
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
All Times Listed are for the Eastern Standard Time Zone
| Thursday, October 15, 2026 | |
|---|---|
| 3:00pm | Welcome and Introduction » Julia Lea Ziegengeist, PharmD, BCOP |
| 3:05pm | OPN and ACCP Hematology/Oncology PRN Journal Club - October 2026 » Michael Tierney |
| 3:35am | Breakout Room + Closing Comments » Julia Lea Ziegengeist, PharmD, BCOP |
Faculty

Julia Lea Ziegengeist, PharmD, BCOP (Moderator)
Clinical Pharmacist Specialist,
Breast Medical Oncology, Pharmacy Services
Levine Cancer, Barbara L. Levine Oncology Breast & Cutaneous Center
Charlotte, NC
Dr. Julia Ziegengeist practices as a Clinical Pharmacist Specialist for solid tumor oncology specializing in breast cancer at Atrium Health Levine Cancer in Charlotte, North Carolina. She completed her PGY-1 Pharmacy Residency and PGY-2 Oncology Pharmacy Residency at Virginia Commonwealth University in Richmond, Virginia in 2018 and 2019, respectively. Since completion of residency, her primary oncology practice site has been within the Levine Cancer Institute Breast Medical Oncology Clinic, where she works alongside providers and APPs to ensure quality cancer care by tailoring treatment options and subsequent toxicity management to individual patients. She is a board-certified oncology pharmacist and her professional interests include patient education, toxicity management, and expansion of clinical pharmacy services within oncology.

Michael Tierney, (Speaker)
PharmD Student
TTUHSC Jerry H. Hodge School of Pharmacy
Dallas, TX
Michael Tierney is a fourth-year Doctor of Pharmacy student at the Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy (TTUHSC SOP) in Dallas, TX. He is currently a pharmacy intern at Children’s Medical Center Dallas and his interests include oncology, infectious diseases, critical care, and pediatrics.
Throughout pharmacy school,Michael has served in several leadership positions, including class president of the Dallas Campus Student Council for all four years, president of the student chapter of Network for Collaborative Oncology Development and Advancement (NCODA) during the 2026-2027 academic year, and as leadership development chair for Phi Lambda Sigma-Beta Pi Chapter during the 2025-2026 academic year.
Following graduation, he intends to pursue PGY1 and PGY2 residencies and obtain board certification in his specialty area of practice. In his personal life, Michael enjoys spending time with his wife and their Miniature Australian Shepherd as well as exploring everything that Dallas has to offer.
Program Planners

Julia Lea Ziegengeist, PharmD, BCOP
Clinical Pharmacist Specialist,
Breast Medical Oncology, Pharmacy Services
Levine Cancer, Barbara L. Levine Oncology Breast & Cutaneous Center
Charlotte, NC
Dr. Julia Ziegengeist practices as a Clinical Pharmacist Specialist for solid tumor oncology specializing in breast cancer at Atrium Health Levine Cancer in Charlotte, North Carolina. She completed her PGY-1 Pharmacy Residency and PGY-2 Oncology Pharmacy Residency at Virginia Commonwealth University in Richmond, Virginia in 2018 and 2019, respectively. Since completion of residency, her primary oncology practice site has been within the Levine Cancer Institute Breast Medical Oncology Clinic, where she works alongside providers and APPs to ensure quality cancer care by tailoring treatment options and subsequent toxicity management to individual patients. She is a board-certified oncology pharmacist and her professional interests include patient education, toxicity management, and expansion of clinical pharmacy services within oncology.

Marshall Winget, PharmD, BCOP
Inpatient Clinical Pharmacist
Malignant Hematology/Bone Marrow Transplant
Duke University Hospital, Durham
Durham, NC
Marshall Winget is a malignant hematology inpatient clinical pharmacist at Duke University Hospital. He earned his undergraduate degree from the University of Minnesota and his Doctor of Pharmacy from the University of North Carolina Eshelman School of Pharmacy. He then completed his PGY1 Pharmacy Practice Residency and PGY2 Oncology Pharmacy Residency at Vanderbilt University Medical Center in Nashville, Tennessee. His professional interests and research focus on lymphomas, cellular therapies, and cardio-oncology.

Shawn Griffin
Oncology Pharmacist/Assistant Clinical Professor
University of California, Irvine
Irvine, California
Shawn Griffin is a Board Certified Oncology Pharmacist and Health Sciences Assistant Clinical Professor in the Department of Clinical Pharmacy Practice at the University of California, Irvine (UCI) School of Pharmacy & Pharmaceutical Sciences. He practices within the Hematopoietic Stem Cell Transplantation and Cellular Therapy Program at the Chao Family Comprehensive Cancer Center. Prior to joining UCI, Griffin worked as a Hematology/Stem Cell Transplant pharmacist at Indiana University Health for five years. He received PharmD from the UNC Eshelman School of Pharmacy and completed a PGY1 Pharmacy and PGY2 Oncology Pharmacy Residency at the University of Florida Health Shands Hospital.
Disclosures
Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.
Planners
*Horizon CME has mitigated and resolved all relevant financial relationships
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Other Contributors
Other Contributors
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Live activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
How to obtain credit for attendance (eligibility requirement and process for obtaining certificate)
To receive documentation of credit, participants must:
Login to the educational portal
Attend the educational activity
Complete the online evaluation form. The last day to access the evaluation is November 16, 2026 at 11:59pm PST*
Attest to the number of hours in attendance in order to generate your certificate
*Requests from learners to claim credit after the evaluation closes will not be granted

Facebook
X
LinkedIn
Forward